PARP Inhibitor Combinations in Prostate Cancer: Expanding Treatment Options

Join us for this interactive live-stream webinar to learn about PARP inhibitor combination therapies for prostate cancer featuring a discussion by expert faculty on the latest evidence on PARPi combinations with AR-targeting agents and with immunotherapy. This event will offer attendees the opportunity to have their questions answered by the expert panel.

Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


  • Single-Agent PARP Inhibitors in Prostate Cancer
  • Understanding the Interdependencies of Targeted Pathways: Rationale for Combinations
  • Phase III PARP Combinations in Prostate Cancer
  • Audience Q&A


Date / Time
Event Details


Program Director
Charles J. Ryan, MD

Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
 Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
Minneapolis, Minnesota

Wassim Abida, MD, PhD

Joaquin Mateo, MD, PhD

Group Leader
Prostate Cancer Translational Research
Vall d'Hebron Institute of Oncology
Attending Physician
Medical Oncology
Vall d'Hebron University Hospital
Barcelona, Spain

Goal Statement
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate new agents and recent findings into the treatment of patients with prostate cancer.

Target Audience
This program is intended for physicians and other healthcare providers who care for men with prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the medical need and rationale for PARP inhibitor–based combinations in prostate cancer with or without DNA damage repair alterations
  • Plan therapeutic strategies using PARP inhibitor–based combinations for metastatic prostate cancer with or without DNA damage repair alterations
  • Evaluate the available clinical evidence on combination therapies including PARP inhibitors with androgen receptor–targeting agents or other therapies in metastatic CRPC
  • Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitor combinations in prostate cancer


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.